How are SRPT strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SRPT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 55.48%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$135.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a SRPT strangle?

The breakeven for the SRPT strangle priced on this page is roughly $15.65 and $20.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SRPT market-implied 1-standard-deviation expected move is approximately 15.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current SRPT implied volatility affect this strangle?

SRPT ATM IV is at 55.48% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

SRPT Strangle Strategy

SRPT (Sarepta Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT (Sarepta Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.99B, a trailing P/E of 30.40, a beta of 0.26 versus the broader market, a 52-week range of 10.42-44.14, average daily share volume of 2.9M, a public-listing history dating back to 1997, approximately 1K full-time employees. These structural characteristics shape how SRPT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.26 indicates SRPT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on SRPT?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current SRPT snapshot

As of May 15, 2026, spot at $17.62, ATM IV 55.48%, IV rank 0.00%, expected move 15.91%. The strangle on SRPT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on SRPT specifically: SRPT IV at 55.48% is on the cheap side of its 1-year range, which favors premium-buying structures like a SRPT strangle, with a market-implied 1-standard-deviation move of approximately 15.91% (roughly $2.80 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SRPT expiries trade a higher absolute premium for lower per-day decay. Position sizing on SRPT should anchor to the underlying notional of $17.62 per share and to the trader's directional view on SRPT stock.

SRPT strangle setup

The SRPT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SRPT near $17.62, the first option leg uses a $19.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SRPT chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SRPT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$19.00	$0.63
Buy 1	Put	$17.00	$0.73

SRPT strangle risk and reward

Net Premium / Debit: -$135.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$135.00
Breakeven(s): $15.65, $20.35
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

SRPT strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on SRPT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$1,564.00
$3.90	-77.8%	+$1,174.52
$7.80	-55.7%	+$785.05
$11.69	-33.6%	+$395.57
$15.59	-11.5%	+$6.09
$19.48	+10.6%	-$86.61
$23.38	+32.7%	+$302.86
$27.27	+54.8%	+$692.34
$31.17	+76.9%	+$1,081.82
$35.06	+99.0%	+$1,471.30

When traders use strangle on SRPT

Strangles on SRPT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SRPT chain.

SRPT thesis for this strangle

The market-implied 1-standard-deviation range for SRPT extends from approximately $14.82 on the downside to $20.42 on the upside. A SRPT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SRPT IV rank near 0.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SRPT at 55.48%. As a Healthcare name, SRPT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SRPT-specific events.

SRPT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SRPT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SRPT alongside the broader basket even when SRPT-specific fundamentals are unchanged. Always rebuild the position from current SRPT chain quotes before placing a trade.

Frequently asked questions

What is a strangle on SRPT?: A strangle on SRPT is the strangle strategy applied to SRPT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SRPT stock trading near $17.62, the strikes shown on this page are snapped to the nearest listed SRPT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SRPT strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SRPT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 55.48%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$135.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SRPT strangle?: The breakeven for the SRPT strangle priced on this page is roughly $15.65 and $20.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SRPT market-implied 1-standard-deviation expected move is approximately 15.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on SRPT?: Strangles on SRPT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SRPT chain.
How does current SRPT implied volatility affect this strangle?: SRPT ATM IV is at 55.48% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.